Core Concepts
High platelet-to-lymphocyte ratio (PLR) in patients with type 2 diabetes undergoing PCI increases the risk of adverse cardiovascular events and stent thrombosis.
Abstract
The study focused on the impact of the platelet-to-lymphocyte ratio (PLR) on patients with type 2 diabetes undergoing percutaneous coronary intervention (PCI). Here are the key points:
Key Takeaways
- High PLR in diabetic patients undergoing PCI linked to increased risk of MACCE and stent thrombosis.
- PLR not associated with adverse outcomes in non-diabetic patients.
Why This Matters
- PLR serves as an inflammatory biomarker.
- Previous studies highlight PLR's significance in evaluating disease activity and prognosis in various disorders.
Study Design
- 8831 adults who underwent PCI were analyzed.
- Patients with high PLR had higher risks of MACCE and stent thrombosis.
- Patients with type 2 diabetes and high PLR require close monitoring post-PCI.
Key Results
- High PLR in diabetic patients associated with increased risk of MACCE and stent thrombosis.
- No significant risk increase in non-diabetic patients with high PLR.
Limitations
- Observational study with potential unadjusted confounders.
- Lack of data on PLR and glycemic status changes during follow-up.
- Findings may have limited generalizability due to the exclusively Chinese population.
Stats
Among patients with type 2 diabetes, those with a high PLR had a significantly higher risk of MACCE compared with those with a low PLR (hazard ratio, 1.53) and stent thrombosis (hazard ratio, 3.79).
During a median 2.4-year follow-up, 663 patients (7.5%) had MACCE and 75 patients (0.85%) had stent thrombosis.
Quotes
"PLR is an easy-to-obtain inflammatory biomarker."
"Results suggest that patients with type 2 diabetes and a high PLR should be closely monitored following PCI."